York Hospital
- Type
- Teaching hospital
- Where
- York, PA
- Medicare CCN
- 390046
- Received
- $219,263 in 209 records, 2020 ($57,004 general, $162,258 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: York Hospital Fuzzy (name and state)
- Nonprofit: YORK HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 27 | $57,004 |
| 2020 | Research payment | 182 | $162,258 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Edwards Lifesciences Corporation | 20 | $67,818 | 2020 |
| Stryker Corporation | 24 | $51,243 | 2020 |
| Boehringer Ingelheim International GmbH | 95 | $20,650 | 2020 |
| Zogenix Inc. | 3 | $18,447 | 2020 |
| Becton, Dickinson and Company | 2 | $12,626 | 2020 |
| Boehringer Ingelheim Pharma GmbH & Co.KG | 3 | $9,657 | 2020 |
| Pharmacyclics LLC, an AbbVie Company | 46 | $9,150 | 2020 |
| Incyte Corporation | 2 | $8,891 | 2020 |
| GW Research Limited | 2 | $5,327 | 2020 |
| TriReme Medical LLC | 3 | $5,300 | 2020 |
| Boston Scientific Corporation | 4 | $3,428 | 2020 |
| Aesculap, Inc. | 1 | $2,942 | 2020 |
| Medtronic Vascular, Inc. | 1 | $2,595 | 2020 |
| Bolton Medical Inc | 1 | $500 | 2020 |
| Eli Lilly and Company | 1 | $462 | 2020 |
| Masimo Corporation | 1 | $223 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 182 | $162,258 |
| Gift | 9 | $49,029 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 16 | $5,157 |
| Grant | 1 | $2,595 |
| Education | 1 | $223 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-23 | Edwards Lifesciences Corporation | $500 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | Partner3 2015-08 | 2020 |
| 2020-12-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-17 | Edwards Lifesciences Corporation | $11,993 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2020 | |
| 2020-12-17 | Edwards Lifesciences Corporation | $500 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | PARTNER3 2015-08 | 2020 |
| 2020-12-15 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-15 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-15 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-15 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-15 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-15 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-15 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-15 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-15 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-15 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-15 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-12-10 | Aesculap, Inc. | $2,942 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-08 | TriReme Medical LLC | $2,100 | Research payment | Cash or cash equivalent | BALLOON CATHETER Device, BALLOON CATHETER | BALLOON CATHETER | 2020 |
| 2020-12-07 | Edwards Lifesciences Corporation | $144 | Research payment | Cash or cash equivalent | PARTNER II (2010-12) | 2020 | |
| 2020-11-16 | Boston Scientific Corporation | $500 | Research payment | Cash or cash equivalent | ACUITY Device, TACHY | NAVIGATE X4 STUDY | 2020 |
| 2020-11-05 | Boehringer Ingelheim International GmbH | $1 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-10-26 | Edwards Lifesciences Corporation | $144 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2020 | |
| 2020-10-22 | Edwards Lifesciences Corporation | $10,042 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2020 | |
| 2020-10-13 | Stryker Corporation | $946 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-10-13 | Stryker Corporation | $354 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-10-13 | Stryker Corporation | $74 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-10-13 | Stryker Corporation | $31 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-10-02 | Boehringer Ingelheim International GmbH | $21 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-10-02 | Boehringer Ingelheim International GmbH | $0 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-10-02 | Boehringer Ingelheim International GmbH | $0 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-10-01 | Edwards Lifesciences Corporation | $1,091 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2020 | |
| 2020-10-01 | Edwards Lifesciences Corporation | $226 | Research payment | Cash or cash equivalent | PARTNER II (2010-12) | 2020 | |
| 2020-10-01 | Edwards Lifesciences Corporation | $141 | Research payment | Cash or cash equivalent | PARTNER II (2010-12) | 2020 | |
| 2020-10-01 | Boehringer Ingelheim International GmbH | $81 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-09-28 | Edwards Lifesciences Corporation | $1,214 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | Early-TAVR Trial #2016-07 | 2020 |
| 2020-09-24 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-09-24 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-09-24 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-09-24 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-09-24 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-09-24 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-09-24 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-09-21 | Boston Scientific Corporation | $176 | Research payment | Cash or cash equivalent | ACUITY Device, TACHY | NAVIGATE X4 STUDY | 2020 |
| 2020-09-17 | Boehringer Ingelheim International GmbH | $2,601 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-09-14 | TriReme Medical LLC | $800 | Research payment | Cash or cash equivalent | BALLOON CATHETER Device, BALLOON CATHETER | BALLOON CATHETER | 2020 |
| 2020-09-09 | Becton, Dickinson and Company | $6,012 | Research payment | Cash or cash equivalent | BD Veritor Device, Diagnostic Systems | Veritor Antigen Assay | 2020 |
| 2020-08-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,049 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-08-26 | Boehringer Ingelheim International GmbH | $842 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-08-25 | Pharmacyclics LLC, an AbbVie Company | $2,500 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-08-24 | Edwards Lifesciences Corporation | $11,077 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2020 | |
| 2020-08-20 | Zogenix Inc. | $4,879 | Research payment | Cash or cash equivalent | ZX008 Drug, Treatment of seizures | A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Childre | 2020 |
| 2020-08-20 | Zogenix Inc. | $781 | Research payment | Cash or cash equivalent | ZX008 Drug, Treatment of seizures | A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Childre | 2020 |
| 2020-08-20 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-08-20 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-08-20 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-08-05 | Becton, Dickinson and Company | $6,614 | Research payment | In-kind items and services | BD Veritor Device, Diagnostic Systems | Veritor Antigen Assay | 2020 |
| 2020-07-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,558 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-07-24 | Boehringer Ingelheim International GmbH | $2,303 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-07-24 | Boehringer Ingelheim International GmbH | $504 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-07-24 | Boehringer Ingelheim International GmbH | $282 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-07-24 | Boehringer Ingelheim International GmbH | $261 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-07-21 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-07-21 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-07-21 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-07-16 | Zogenix Inc. | $12,787 | Research payment | Cash or cash equivalent | ZX008 Drug, Treatment of seizures | A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Childre | 2020 |
| 2020-07-09 | Edwards Lifesciences Corporation | $226 | Research payment | Cash or cash equivalent | PARTNER II (2010-12) | 2020 | |
| 2020-07-07 | Boehringer Ingelheim International GmbH | $81 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-07-06 | Stryker Corporation | $459 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-07-06 | Stryker Corporation | $127 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-07-06 | Stryker Corporation | $44 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-07-06 | Stryker Corporation | $29 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-07-03 | Boehringer Ingelheim International GmbH | $21 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-07-03 | Boehringer Ingelheim International GmbH | $18 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-07-03 | Boehringer Ingelheim International GmbH | $18 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-07-03 | Boehringer Ingelheim International GmbH | $9 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-07-02 | Edwards Lifesciences Corporation | $9,040 | Research payment | Cash or cash equivalent | PARTNER3 2015-08 | 2020 | |
| 2020-07-01 | Boehringer Ingelheim International GmbH | $282 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-06-16 | Boehringer Ingelheim International GmbH | $956 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-06-16 | Boehringer Ingelheim International GmbH | $956 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-06-16 | Boehringer Ingelheim International GmbH | $956 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-06-16 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-06-16 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-06-16 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-06-16 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-06-16 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-06-16 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-06-16 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-06-16 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-06-10 | Medtronic Vascular, Inc. | $2,595 | Grant | In-kind items and services | IN.PACT AV Device, Drug-Coated Balloons | 2020 | |
| 2020-06-05 | GW Research Limited | $2,898 | Research payment | Cash or cash equivalent | GWEP1521 | 2020 | |
| 2020-06-01 | Stryker Corporation | $10,190 | Gift | In-kind items and services | INTOUCH W/ZOOM Device, PATIENT CARE - PC | 2020 | |
| 2020-06-01 | Stryker Corporation | $10,190 | Gift | In-kind items and services | INTOUCH W/ZOOM Device, PATIENT CARE - PC | 2020 | |
| 2020-06-01 | Stryker Corporation | $10,190 | Gift | In-kind items and services | INTOUCH W/ZOOM Device, PATIENT CARE - PC | 2020 | |
| 2020-06-01 | Stryker Corporation | $4,716 | Gift | In-kind items and services | ISOLIBRIUM Device, PATIENT CARE - PC | 2020 | |
| 2020-06-01 | Stryker Corporation | $4,716 | Gift | In-kind items and services | ISOLIBRIUM Device, PATIENT CARE - PC | 2020 | |
| 2020-06-01 | Stryker Corporation | $4,716 | Gift | In-kind items and services | ISOLIBRIUM Device, PATIENT CARE - PC | 2020 | |
| 2020-05-26 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-05-26 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-05-26 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-05-22 | Boehringer Ingelheim International GmbH | $1,774 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-05-22 | Boehringer Ingelheim International GmbH | $887 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-05-22 | Boehringer Ingelheim International GmbH | $693 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-05-22 | Boehringer Ingelheim International GmbH | $693 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-05-22 | Boehringer Ingelheim International GmbH | $693 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-05-22 | Boehringer Ingelheim International GmbH | $282 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-05-22 | Boehringer Ingelheim International GmbH | $59 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-05-22 | Boehringer Ingelheim International GmbH | $52 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-05-22 | Boehringer Ingelheim International GmbH | $52 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-05-22 | Boehringer Ingelheim International GmbH | $47 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-05-22 | Boehringer Ingelheim International GmbH | $17 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-05-22 | Boehringer Ingelheim International GmbH | $17 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-05-12 | Boehringer Ingelheim International GmbH | $693 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-05-06 | Bolton Medical Inc | $500 | Research payment | Cash or cash equivalent | Treovance Device, Device | Treovance | 2020 |
| 2020-05-04 | Boehringer Ingelheim International GmbH | $40 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-05-04 | Boehringer Ingelheim International GmbH | $25 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-05-04 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-05-04 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-05-04 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-05-04 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-05-04 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-05-04 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-05-04 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-05-01 | Stryker Corporation | $894 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-05-01 | Stryker Corporation | $371 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-05-01 | Stryker Corporation | $109 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-05-01 | Stryker Corporation | $32 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-04-20 | Boehringer Ingelheim International GmbH | $141 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-04-14 | Boehringer Ingelheim International GmbH | $956 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-04-09 | Edwards Lifesciences Corporation | $7,480 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2020 | |
| 2020-04-02 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-04-02 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-04-02 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-04-02 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-04-02 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-04-02 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-04-02 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-04-02 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-04-02 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-04-02 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-04-02 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-04-01 | Boehringer Ingelheim International GmbH | $336 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-04-01 | Masimo Corporation | $223 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2020 | |
| 2020-04-01 | Edwards Lifesciences Corporation | $194 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | Partner3 2015-08 | 2020 |
| 2020-03-23 | Edwards Lifesciences Corporation | $432 | Research payment | Cash or cash equivalent | PARTNER II (2010-12) | 2020 | |
| 2020-03-19 | Edwards Lifesciences Corporation | $500 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | Early-TAVR Trial #2016-07 | 2020 |
| 2020-03-18 | Boston Scientific Corporation | $638 | Research payment | Cash or cash equivalent | ACUITY Device, TACHY | NAVIGATE X4 STUDY | 2020 |
| 2020-03-17 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-03-17 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-03-17 | Pharmacyclics LLC, an AbbVie Company | $50 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-03-09 | Edwards Lifesciences Corporation | $9,067 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2020 | |
| 2020-03-06 | Edwards Lifesciences Corporation | $3,300 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | PARTNER II (2010-12) | 2020 |
| 2020-03-06 | Edwards Lifesciences Corporation | $500 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | Partner3 2015-08 | 2020 |
| 2020-03-03 | Boehringer Ingelheim International GmbH | $61 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-03-03 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-03-03 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-03-03 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-02-26 | Incyte Corporation | $3,500 | Research payment | Cash or cash equivalent | Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S | 2020 | |
| 2020-02-25 | Boehringer Ingelheim International GmbH | $796 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-02-25 | Boehringer Ingelheim International GmbH | $81 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-02-18 | Boston Scientific Corporation | $2,114 | Research payment | Cash or cash equivalent | ACUITY Device, TACHY | NAVIGATE X4 STUDY | 2020 |
| 2020-02-14 | Boehringer Ingelheim International GmbH | $81 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-02-13 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-02-13 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-02-05 | Boehringer Ingelheim International GmbH | $30 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-02-05 | Boehringer Ingelheim International GmbH | $26 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-02-05 | Boehringer Ingelheim International GmbH | $25 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-02-05 | Boehringer Ingelheim International GmbH | $23 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-02-05 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-02-05 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-02-05 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-02-05 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-02-05 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-02-05 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-02-05 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-01-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,049 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-01-28 | Eli Lilly and Company | $462 | Research payment | In-kind items and services | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD | 2020 | |
| 2020-01-28 | Boehringer Ingelheim International GmbH | $81 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-01-22 | Incyte Corporation | $5,391 | Research payment | Cash or cash equivalent | Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S | 2020 | |
| 2020-01-22 | GW Research Limited | $2,429 | Research payment | Cash or cash equivalent | GWEP1521 | 2020 | |
| 2020-01-20 | TriReme Medical LLC | $2,400 | Research payment | Cash or cash equivalent | BALLOON CATHETER Device, BALLOON CATHETER | BALLOON CATHETER | 2020 |
| 2020-01-14 | Stryker Corporation | $1,190 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-01-14 | Stryker Corporation | $932 | Gift | In-kind items and services | INTOUCH W/ZOOM Device, PATIENT CARE - PC | 2020 | |
| 2020-01-14 | Stryker Corporation | $431 | Gift | In-kind items and services | ISOLIBRIUM Device, PATIENT CARE - PC | 2020 | |
| 2020-01-14 | Stryker Corporation | $323 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-01-14 | Stryker Corporation | $137 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-01-14 | Stryker Corporation | $29 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-01-06 | Boehringer Ingelheim International GmbH | $65 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-01-06 | Boehringer Ingelheim International GmbH | $52 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-01-06 | Boehringer Ingelheim International GmbH | $41 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-01-06 | Boehringer Ingelheim International GmbH | $30 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-01-06 | Boehringer Ingelheim International GmbH | $30 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-01-06 | Boehringer Ingelheim International GmbH | $26 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-01-06 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-01-06 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-01-06 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-01-06 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-01-06 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
| 2020-01-06 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2020 |
| 2020-01-06 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and heart failure (HFpEF) | 2020 |
The latest 200 records of 209.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In York, PA, county York County, PA, state Pennsylvania; placed by its city name.
| Measure | Place (city or town) York, PA | County York County, PA | State Pennsylvania |
|---|---|---|---|
| Population B01003 | 44,938 | 462,924 | 13,018,639 |
| Population, 2020 census P1 | 44,800 | 456,438 | 13,002,700 |
| Median age B01002 | 34.3 | 41.1 | 40.9 |
| Under 18 B01001 | 23.9% | 21.9% | 20.4% |
| 65 and over B01001 | 13.1% | 18.8% | 19.5% |
| Households B11001 | 17,893 | 181,583 | 5,274,853 |
| Foreign born B05002 | 11.1% | 4.1% | 7.7% |
| Median household income B19013 | $48,420 | $84,829 | $77,971 |
| Median family income B19113 | $54,727 | $102,186 | $100,262 |
| Per capita income B19301 | $26,308 | $41,601 | $44,355 |
| Poverty rate B17001 | 21.1% | 8.4% | 11.7% |
| Unemployment rate B23025 | 10.7% | 4.5% | 5.3% |
| Civilian labor force B23025 | 23,179 | 245,693 | 6,684,175 |
| Mean commute (minutes) B08013 | 23.1 | 26.3 | 26.3 |
| Bachelor's degree or higher B15003 | 17.5% | 27.6% | 35.2% |
| Housing units B25001 | 19,505 | 189,857 | 5,806,452 |
| Owner-occupied B25003 | 43.7% | 76.3% | 69.3% |
| Renters B25003 | 56.3% | 23.7% | 30.7% |
| Median home value B25077 | $119,700 | $248,600 | $254,500 |
| Median gross rent B25064 | $1,014 | $1,193 | $1,209 |
| White, not Hispanic B03002 | 33.6% | 78.9% | 73.0% |
| Black B03002 | 24.1% | 5.8% | 10.3% |
| Hispanic or Latino B03002 | 36.6% | 9.6% | 8.7% |
| Asian B03002 | 1.0% | 1.5% | 3.8% |
| American Indian and Alaska Native B03002 | 0.0% | 0.0% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in York, PA.
Comments